What are the treatment options for bladder cancer based on tumor stage (non‑muscle‑invasive versus muscle‑invasive/metastatic)?

Treatment Options for Bladder Cancer

Treatment for bladder cancer is fundamentally determined by whether the tumor is non-muscle-invasive (NMIBC) or muscle-invasive/metastatic, with approximately 75% of patients presenting with NMIBC that requires transurethral resection followed by risk-stratified intravesical therapy, while muscle-invasive disease demands radical cystectomy with perioperative chemotherapy or trimodal bladder-sparing therapy in selected cases. 1, 2

Non-Muscle-Invasive Bladder Cancer (NMIBC)

Initial Management

• Transurethral resection of bladder tumor (TURBT) is the cornerstone of initial treatment, with complete resection of all visible tumor tissue essential 1
• The resected specimen must include lamina propria and detrusor muscle for accurate staging 1
• Bladder biopsies from suspicious areas or mapping biopsies should be obtained in patients with positive urine cytology or history of high-grade NMIBC 1

Risk-Stratified Adjuvant Therapy

For intermediate-risk and high-risk NMIBC:

• Intravesical Bacillus Calmette-Guérin (BCG) therapy remains the standard adjuvant treatment after TURBT 1, 2
• However, approximately 30-40% of patients develop BCG-unresponsive disease despite adequate BCG administration 3, 4

For BCG-unresponsive NMIBC (critical decision point):

The landscape has dramatically shifted with FDA-approved bladder-preserving alternatives:

1. Pembrolizumab (immune checkpoint inhibitor) - FDA approved for BCG-unresponsive disease 3, 5
2. Nadofaragene firadenovec (gene therapy) - FDA approved, showing complete response rates between 42-100% in trials 3, 5
3. N-803 in combination with BCG - FDA approved 3

Emerging therapies under investigation:

• TAR-200 (novel intravesical drug delivery system) 5
• Cretostimogene grenadenorepvec (oncolytic virus therapy) 3
• Detalimogene voraplasmid 3
• CG0070 (viral therapy) 5
• Durvalumab (immune checkpoint inhibitor) 5

Radical cystectomy is recommended for BCG-unresponsive disease when bladder-preserving options fail or are unsuitable, though its invasiveness and quality of life impact make it challenging in real-world practice 3, 4

Low-Grade NMIBC

• De-escalation strategies including active surveillance and novel adjuvant therapies are being explored to reduce repeated TURBT procedures 5

Muscle-Invasive Bladder Cancer (MIBC)

Standard Curative Approach

Radical cystectomy with pelvic lymph node dissection plus neoadjuvant chemotherapy is the recommended treatment for fit patients with clinical T2-T4a disease. 1, 6

Key components:

• Neoadjuvant cisplatin-based chemotherapy before radical cystectomy provides a 5% improvement in 5-year overall survival (Level 1 evidence) 4, 6
• Radical cystectomy should be performed in experienced centers with minimum case load of 10 procedures per year 6
• Open and robotic approaches show comparable outcomes when performed by experienced surgeons 6
• Sexuality-sparing cystectomy benefits selected patients but is not standard therapy 6

Important caveat: Many patients are cisplatin-ineligible due to comorbidities, and NAC is often underused due to fear of delaying surgery in non-responders 4

Bladder-Sparing Alternative (Trimodal Therapy)

For well-selected patients without carcinoma in situ and after maximal TURBT, chemoradiation offers comparable 5-year survival (29-73%) to radical cystectomy. 6, 7

Selection criteria are critical:

• Absence of carcinoma in situ
• Maximal transurethral resection achieved
• Good bladder function
• Patient acceptance of ongoing surveillance and salvage cystectomy risk 4, 7

Quality of life advantage: Patients undergoing bladder-sparing therapy demonstrate better outcomes in quality of life and sociability compared to radical cystectomy 7

Perioperative Immunotherapy

• Can be offered in clinical trial settings 6
• Showing promise but not yet standard of care

Adjuvant Therapy

• Adjuvant chemotherapy should be considered if neoadjuvant chemotherapy was not given 6

Metastatic Bladder Cancer

First-Line Therapy

For cisplatin-eligible fit patients:

• Cisplatin-based combination chemotherapy remains the first choice 1, 6

For cisplatin-ineligible patients (algorithmic approach):

1. If PD-L1 positive: Immunotherapy (checkpoint inhibitors) is recommended 6
2. If PD-L1 negative: Carboplatin-based chemotherapy is recommended 6

Second-Line Therapy

Pembrolizumab is the recommended second-line treatment for metastatic disease. 6

Additional Options

• Antibody-drug conjugates have been added as treatment options for metastatic disease 8
• Postchemotherapy surgery (consolidative surgery) may prolong survival in patients who respond to chemotherapy 6

Survival Outcomes

• Checkpoint inhibitors in metastatic disease have extended overall survival to 15-17 months 9
• This represents significant improvement over historical outcomes

Critical Surveillance Considerations

For high-risk NMIBC:

• Upper tract imaging (CT urography or MRI urography) should be performed to screen for synchronous upper urinary tract urothelial carcinoma, which occurs in 2.5% of patients 1

Metastatic work-up for high-risk patients:

• CT chest, abdomen, and pelvis
• Liver function tests 1

Common Pitfalls to Avoid

1. Inadequate TURBT: Failure to obtain lamina propria and detrusor muscle in resection specimens leads to inaccurate staging 1
2. Delayed treatment in MIBC: Underuse of neoadjuvant chemotherapy due to unfounded fears of delaying surgery 4
3. Inappropriate patient selection for bladder preservation: Offering trimodal therapy to patients with extensive CIS or poor bladder function 4, 6
4. Ignoring quality of life: Quality of life should be monitored in all phases of treatment and follow-up 6
5. Missing synchronous upper tract disease: Failing to image upper tracts in high-risk NMIBC 1

The treatment paradigm for bladder cancer has evolved significantly, particularly with FDA-approved immunotherapies and gene therapies for BCG-unresponsive NMIBC 3, offering genuine bladder-preserving alternatives where radical cystectomy was previously the only option. For muscle-invasive disease, the evidence strongly supports neoadjuvant chemotherapy before cystectomy in eligible patients 4, 6, while carefully selected patients can achieve comparable survival with trimodal bladder-sparing approaches 7.